Stay updated on M7824 and Topotecan in Relapsed SCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.

Latest updates to the M7824 and Topotecan in Relapsed SCLC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed background information on Small Cell Lung Cancer (SCLC) and the addition of a new version revision. The study's primary objective and eligibility criteria remain intact, but the core content regarding treatment options and mechanisms has been deleted.SummaryDifference56%
- Check29 days agoChange DetectedThe page has been updated to reflect a new revision (v2.14.4) and indicates that results have been submitted, replacing the previous status of no results posted.SummaryDifference0.2%
- Check36 days agoNo Change Detected
- Check58 days agoChange DetectedThe page has been updated to reflect that the study is now active and not recruiting, with a new actual date of 2025-03-06, replacing the previous estimated date of 2025-03-01.SummaryDifference2%
- Check65 days agoChange DetectedThe webpage has updated its date references, removing several past dates and adding new ones for March 2025.SummaryDifference0.8%
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
Stay in the know with updates to M7824 and Topotecan in Relapsed SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.